Hereditary Angioedema Market Report 2026

Hereditary Angioedema Market Overview

• Hereditary Angioedema market size has reached to $2.81 billion in 2025 • Expected to grow to $4.15 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Rising Prevalence Of Rare Diseases Driving The Growth Of The Market Due To Increasing Demand For Specialized Treatments • Market Trend: Innovative Oral Treatment Marks Breakthrough In Rare Disease Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hereditary Angioedema Market?

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling in the skin, gastrointestinal tract, and airways due to C1 esterase inhibitor deficiency or dysfunction. It is caused by genetic mutations affecting the complement system, leading to excessive bradykinin production. HAE can be life-threatening if airway swelling occurs, requiring prompt treatment with C1 inhibitor replacement or bradykinin-targeted therapies. The main types of hereditary angioedema are hereditary angioedema type I and hereditary angioedema type II. Angioedema Type I is the most common form of hereditary angioedema (HAE) caused by a deficiency of C1 esterase inhibitor (C1-INH), leading to uncontrolled bradykinin production and recurrent swelling episodes. Treatment for HAE is typically divided into prophylaxis and on-demand options, with different drug classes such as C1 esterase inhibitors, bradykinin receptor antagonists, kallikrein inhibitors, and other drug classes. These treatments are administered through various routes, including subcutaneous, intravenous, and oral methods, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Hereditary Angioedema Market Growth Forecast?

The hereditary angioedema market size is expected to see strong growth in the next few years. It will grow to $4.15 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to expansion of novel oral and subcutaneous therapies, increasing investment in rare disease drug development, rising adoption of personalized medicine approaches, growth in genetic screening programs, improved long-term disease management strategies. Major trends in the forecast period include increasing adoption of targeted bradykinin therapies, rising use of prophylactic treatment regimens, growing focus on early genetic diagnosis, expansion of home-based self-administration therapies, enhanced patient-centric treatment approaches.

Global Hereditary Angioedema Market Segmentation

1) By Type: Hereditary Angioedema Type I, Hereditary Angioedema Type II 2) By Treatment Type: Prophylaxis, On-demand 3) By Drug Class: C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors, Other Drug Classes 4) By Route Of Administration: Subcutaneous, Intravenous, Oral 5) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency, Low C1-Inhibitor Levels 2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels, Dysfunctional C1-Inhibitor, Genetic Mutations In SERPING1 Gene

What Is The Driver Of The Hereditary Angioedema Market?

The growing prevalence of rare diseases is expected to propel the growth of the hereditary angioedema market going forward. Rare diseases, also known as orphan diseases, refer to medical conditions that affect a small percentage of the population. The increasing prevalence of rare diseases is due to multiple factors, such as progress in medical research, changes in population demographics, and environmental impacts. Hereditary angioedema (HAE) is a significant rare disease, highlighting the need for specialized treatments and awareness due to its life-threatening swelling episodes. Its rarity and genetic nature make early diagnosis and targeted therapies essential for effective management and improved patient outcomes. For instance, in January 2025, according to the The American Cancer Society, a US-based professional organization, in 2025, an estimated 59,660 new cases of oral cavity and oropharyngeal cancer are expected to be diagnosed, and approximately 12,770 people are projected to die from these cancers. Therefore, the growing prevalence of rare diseases is driving the growth of the hereditary angioedema industry.

Key Players In The Global Hereditary Angioedema Market

Major companies operating in the hereditary angioedema market are Takeda Pharmaceutical Company Limited, CSL Limited, Sanofi S.A., Pharming Group N.V., BioCryst Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intellia Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Astria Therapeutics Inc., Pharvaris N.V., Adverum Biotechnologies Inc., ADARx Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Spark Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc.

Global Hereditary Angioedema Market Trends and Insights

Major companies operating in the hereditary angioedema market are developing innovative products, such as oral plasma kallikrein inhibitors, to provide more convenient and effective on-demand treatment options for patients. Oral plasma kallikrein inhibitors are drugs that block plasma kallikrein to prevent excessive bradykinin production, primarily used for treating hereditary angioedema. For instance, in September 2024, KalVista Pharmaceuticals, Inc., a US-based pharmaceutical company, announced that the FDA has accepted its new drug application (NDA) for sebetralstat. This investigational oral plasma kallikrein inhibitor is intended for the on-demand treatment of hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 and older. Sebetralstat provides a new treatment approach by targeting and inhibiting plasma kallikrein activity. The acceptance of the NDA represents a major milestone toward potential approval and commercialization.

What Are Latest Mergers And Acquisitions In The Hereditary Angioedema Market?

In July 2023, BioCryst Pharmaceuticals, Inc., a US-based biopharmaceutical company, partnered with Er-Kim Pharmaceuticals to commercialize ORLADEYO in Turkey. Through this partnership, BioCryst Pharmaceuticals, Inc. seeks to improve access to ORLADEYO (berotralstat) for hereditary angioedema patients in Turkey while strengthening its presence in the global rare disease market. Er-Kim Pharmaceuticals is a Turkey-based company focused on developing, manufacturing, and marketing high-quality medicines across various therapeutic areas.

Regional Outlook

North America was the largest region in the hereditary angioedema market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hereditary Angioedema Market?

The hereditary angioedema market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, acute attack management, and long-term prevention. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary angioedema market also includes sales of plasma-derived products, biologics, and therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hereditary Angioedema Market Report 2026?

The hereditary angioedema market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary angioedema industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.